Prostate Pathology — BPH and Carcinoma

BPH Pathophysiology

• Androgen-dependent epithelial and stromal proliferation: BPH development is fundamentally dependent on dihydrotestosterone (DHT), the potent metabolite of testosterone produced by 5-alpha reductase type II in stromal and epithelial cells. The transition zone epithelium possesses increased androgen receptor density and enhanced enzymatic conversion of testosterone to DHT compared to peripheral zones, explaining the preferential location of BPH growth. Aging-related alterations in the stromal-epithelial interaction and increased local DHT production drive progressive hyperplasia with mixed glandular and smooth muscle proliferation.

• Stromal-epithelial interactions and growth factor signaling: Proliferation in BPH involves paracrine and autocrine signaling via fibroblast growth factors (FGF), vascular endothelial growth factor (VEGF), and transforming growth factor-beta (TGF-β), which are upregulated in hyperplastic tissue. Smooth muscle cells in the prostate stroma express α-1 adrenergic receptors that mediate contraction; increased smooth muscle mass and tone in BPH contribute to urinary obstruction independent of glandular volume. Histological evidence reveals both epithelial hyperplasia (increased glandular components with preserved architecture) and stromal hyperplasia (increased fibroblasts and smooth muscle), with stromal components often predominating.

• Mechanical obstruction and detrusor dysfunction: Progressive BPH causes urethral compression and increased urethral resistance, leading to obstructive LUTS (weak stream, hesitancy, incomplete emptying). Secondary effects include detrusor overactivity (irritative symptoms: frequency, urgency, nocturia) due to chronic outlet obstruction triggering compensatory smooth muscle hyperplasia and neurogenic sensitization of the bladder. Elevated intraprostatic pressure and impaired urinary flow contribute to urinary retention and hydronephrosis in severe cases.

Prostate Cancer Pathophysiology

• Multi-step carcinogenesis and genetic alterations: Prostatic adenocarcinoma arises through sequential accumulation of genetic and epigenetic changes in luminal epithelial cells. Key alterations include loss of NKX3.1 (early event), PTEN deletion, TP53 mutations, and BRCA2 alterations conferring genome instability. Oncogenic ERG/TMPRSS2 fusions (present in ~40% of cases) result from chromosomal rearrangements activating ETS family transcription factors. Androgen receptor (AR) mutations and amplification promote continued growth despite castration, explaining progression to castration-resistant prostate cancer (CRPC).

• Androgen receptor signaling and hormone dependence: Unlike BPH, prostate cancer cells typically harbor constitutively active AR mutations or AR gene amplification that sustains proliferation in low-androgen states. Luminal differentiation programs are disrupted, and cells acquire alternative survival pathways including increased PI3K/Akt signaling and glucocorticoid receptor activation, enabling progression to hormone-refractory disease. AR-mediated transcription in cancer cells drives expression of PSA and other growth-promoting genes; paradoxically, AR remains essential even in metastatic CRPC, explaining clinical responses to newer AR-targeted agents.

• Epithelial-mesenchymal transition (EMT) and metastatic progression: Aggressive cancers exhibit loss of E-cadherin expression and gain of mesenchymal markers (vimentin, N-cadherin), enabling invasion through the prostate capsule and migration to regional lymph nodes and bone. Osteoblastic bone metastases result from tumor-derived RANKL and TGF-β secretion stimulating osteoblast proliferation; the characteristic sclerotic (osteoblastic) pattern distinguishes prostate cancer bone metastases from osteolytic lesions seen in other malignancies. Inactivation of p53 and Rb pathways promotes transition to neuroendocrine carcinoma, an aggressive variant resistant to hormonal therapy.

BPH Risk Factors

• Age and intact testicular function: Age is the strongest risk factor; BPH incidence increases dramatically after age 50, with histological evidence present in >90% of men by age 80. Presence of functional testes and normal/elevated testosterone is essential; BPH does not develop in castrated males, emphasizing hormonal dependence.

• Genetic predisposition and ethnicity: Family history of BPH increases risk; polymorphisms in genes encoding steroid 5-alpha reductase and androgen receptor influence susceptibility. African American men demonstrate higher prevalence and earlier onset of BPH-related symptoms compared to Caucasian or Asian populations.

• Metabolic factors: Obesity, metabolic syndrome, and elevated serum insulin levels correlate with increased BPH risk, possibly through altered androgen metabolism and increased growth factor signaling.

Prostate Cancer Risk Factors

• Age, ethnicity, and family history: Prostate cancer risk increases exponentially after age 65; African American men exhibit 1.6-fold higher incidence and more aggressive disease with earlier presentation. Hereditary prostate cancer (BRCA1/BRCA2 mutations, Lynch syndrome) accounts for 5-10% of cases and predicts earlier onset and worse prognosis.

• Androgenic factors: Unlike BPH, the relationship between testosterone and prostate cancer risk is complex ("androgen paradox"); some studies suggest higher testosterone increases risk, while others show U-shaped or J-shaped relationships. Finasteride (5-alpha reductase inhibitor) reduces cancer incidence by ~25% in the PCPT trial, but with a slight increase in high-grade cancers.

• Inflammation and infectious agents: Chronic prostatitis and elevated PSA may indicate increased cancer risk. Human papillomavirus (HPV) and Propionibacterium acnes have been proposed as potential etiologic cofactors, though causality remains unestablished. Histological evidence of inflammation correlates with cancer development in some cohorts.

• Dietary and environmental factors: High saturated fat intake and dairy consumption show modest associations with increased risk. Vitamin E and selenium supplementation showed no protective effect in large trials (SELECT trial). Occupational cadmium exposure carries increased risk.

BPH Clinical Features

• Lower urinary tract symptoms (LUTS): The hallmark of symptomatic BPH includes obstructive symptoms (weak urinary stream, hesitancy, straining, sensation of incomplete emptying, post-void dribbling, terminal dribbling) and irritative symptoms (frequency, urgency, nocturia, especially nocturnal urgency). Nocturia (typically ≥2 episodes per night) is the most bothersome symptom for patients and correlates with detrusor overactivity superimposed on outlet obstruction.

• Physical examination findings: Enlarged, firm, smooth, symmetric prostate on digital rectal examination (DRE) with preserved median groove is classic for BPH. The prostate may be massively enlarged (>60g) without proportional symptom severity, reflecting variable individual sensitivity to obstruction and detrusor compensation.

• Laboratory and imaging correlates: Elevated post-void residual (PVR) urine volume (>100 mL indicating retention), reduced peak flow rate (<12 mL/sec on uroflowmetry), and elevated post-void residual volume on ultrasound. Serum creatinine elevation or hydronephrosis on renal ultrasound indicates obstructive uropathy with renal compromise in severe cases. PSA elevation is common in enlarged glands (>1 ng/mL per 1 gram of prostate tissue) but is NOT specific for cancer.

• Acute complications: Acute urinary retention (painful inability to void) may occur precipitously, often triggered by decompensation with infection, medications (anticholinergics, sympathomimetics), or alcohol excess. Recurrent urinary tract infections and bladder stones develop from stasis and incomplete emptying.

Prostate Cancer Clinical Presentation

• Early-stage asymptomatic disease: Most localized prostate cancers are asymptomatic at diagnosis, discovered via elevated PSA on screening or incidentally at biopsy for benign indication. PSA elevation may precede symptoms by years; screening-detected cancers have better stage distribution but include overdiagnosed, indolent tumors.

• Advanced disease and obstructive symptoms: Irritative and obstructive LUTS (dysuria, frequency, hesitancy, weak stream) occur when tumors occlude the urethra or compress the bladder outlet, mimicking BPH clinically. Locally advanced tumors may cause gross hematuria, hemospermia, and perineal or rectal pain from direct invasion.

• Metastatic disease manifestations: Bone pain (often in lumbar spine, pelvis, femur) is the most common presenting symptom of metastatic disease, resulting from sclerotic (osteoblastic) bone metastases visible as increased density on X-ray. Lower extremity lymphedema and lower extremity weakness or paralysis (from epidural spinal cord compression) represent oncologic emergencies. Constitutional symptoms (weight loss, fatigue, night sweats) appear with advanced disease.

• Laboratory findings: Elevated PSA (>4.0 ng/mL conventionally, though newer risk calculators use age-stratified cutoffs); PSA velocity and PSA density assist risk stratification. Elevated alkaline phosphatase and bone-specific alkaline phosphatase suggest bone metastases. Elevated lactate dehydrogenase (LDH) and anemia may indicate advanced disease or neuroendocrine differentiation.

BPH Diagnosis

• Clinical assessment and symptom scoring: International Prostate Symptom Score (IPSS) questionnaire quantifies symptom severity (0-35 points: mild, moderate, or severe symptoms). History of gradual onset progressive LUTS, nocturia, and weak stream in an older male is highly suggestive. Digital rectal examination demonstrating smooth, diffuse, symmetric prostate enlargement without induration confirms benign pathology; hard nodules or asymmetry raise suspicion for cancer.

• Uroflowmetry and post-void residual: Peak flow rate <12 mL/sec indicates obstruction; post-void residual >100 mL suggests significant outlet obstruction or detrusor dysfunction. These objective measures correlate with symptom severity and help guide intervention decisions.

• Imaging (transrectal ultrasound, MRI): Transrectal ultrasound (TRUS) visualizes the prostate as a hypoechoic nodular enlarged gland with prominent transition zone. Multiparametric MRI (anatomic T2-weighted plus diffusion, dynamic contrast enhancement, and spectroscopy) better assesses prostate volume and can identify suspicious cancer foci, though not routinely used for BPH diagnosis alone.

• Histopathology (rarely obtained in BPH): When tissue is obtained (e.g., from TURP specimen), histology reveals benign adenomatous hyperplasia with enlarged acini lined by normal two-layer epithelium (luminal columnar cells + underlying basal cells), increased smooth muscle and fibrous stroma, and nodular architecture with preserved glandular differentiation. Absence of cellular atypia, mitotic figures, and basal cell layer disruption confirms benign diagnosis and excludes cancer.

Prostate Cancer Diagnosis

• PSA elevation and risk stratification: Serum PSA >4.0 ng/mL (using traditional threshold; modern risk calculators use age-specific cutoffs and PSA velocity) prompts further evaluation. PSA density (PSA/prostate volume) >0.15 ng/mL/mL and PSA velocity >0.75 ng/mL/year increase cancer suspicion. Free PSA percentage <25% of total PSA suggests higher cancer probability.

• Transrectal ultrasound-guided biopsy: Systematic 12-core transrectal biopsy is the gold standard for cancer diagnosis. Hypoechoic nodules on TRUS may guide targeted sampling, though echoic appearance is not definitively predictive. Contemporary protocols include MRI-guided biopsy for improved cancer detection, particularly avoiding oversampling of benign tissue.

• Histopathological diagnosis and grading: Adenocarcinoma is diagnosed by invasion of malignant acini through the prostatic capsule or into periprostatic tissue, with loss of the basal cell layer (demonstrated by cytokeratin 34βE12 or p63 immunostaining highlighting absent basal cells in cancer nests).

• Gleason pattern 1-2: Well-formed glands, minimal nuclear pleomorphism (rarely seen in contemporary biopsies)
• Gleason pattern 3: Discrete glands with moderate size variation and infiltrative margins
• Gleason pattern 4: Fused/cribriform glands, ill-defined margins, increased nuclear atypia
• Gleason pattern 5: Solid sheets, single infiltrating cells, marked nuclear pleomorphism, necrosis
• Gleason score = primary (most common) pattern + secondary (second most common) pattern; score ranges 3-10. Grade groups (GG1-5) reclassify scores: GG1 (3+3=6), GG2 (3+4=7), GG3 (4+3=7), GG4 (4+4, 3+5, 5+3=8-9), GG5 (4+5, 5+4, 5+5=9-10).

• Molecular and immunohistochemical markers: ERG immunostaining (positive in ~40% via TMPRSS2-ERG fusion) identifies a molecular subtype but does not influence initial grading. PTEN loss on immunohistochemistry correlates with aggressive behavior. p53 overexpression and Ki-67 proliferation index are research tools; p16 loss suggests high-grade disease.

• Gross pathology appearance: Prostate cancer typically appears as tan-white, gritty, infiltrative nodules with ill-defined borders, often in the peripheral zone. Advanced tumors show gray-white infiltrative masses with possible capsular penetration. Cystic degeneration and necrosis are seen in advanced cases. Fresh tissue often exhibits a gritty texture on cut surface due to desmoplastic stromal response.

• TNM staging and risk stratification:
• T stage: T1 (clinically inapparent, incidental finding), T2 (organ-confined), T3 (extraprostatic extension), T4 (invasion of bladder, rectum)
• N stage: N0 (no regional node involvement), N1 (regional lymph node metastases)
• M stage: M0 (no metastases), M1a (non-regional lymph nodes), M1b (bones), M1c (other distant sites)
• Risk stratification (NCCN): Favorable vs. intermediate vs. unfavorable intermediate vs. high-risk vs. very-high-risk based on PSA, Gleason grade group, and T stage

• Advanced imaging (CT, bone scan, PET): Bone scan or PSMA PET-CT identifies metastases in high-risk patients. Pelvic MRI or CT assesses local staging (capsular extension, seminal vesicle invasion, lymph node involvement).

BPH Management

• Watchful waiting and lifestyle modification: Initial strategy for mild-to-moderate symptoms (IPSS <8 or 8-19 with patient acceptance) involves symptom monitoring, fluid restriction, **caffeine/

Complications of BPH (obstruction-driven)

• Acute urinary retention — emergency: sudden painful inability to void with a tense suprapubic mass; precipitated by anticholinergics, sympathomimetics (decongestants), alcohol, or infection. Immediate urethral catheterization is the next step (AUA BPH guideline). Watch for post-obstructive diuresis and transient hematuria after rapid decompression.
• Bilateral hydronephrosis and post-renal azotemia — emergency when creatinine is rising: chronically elevated bladder pressure is transmitted retrograde; signaled by rising creatinine plus hydronephrosis on renal ultrasound. Relief of obstruction reverses it if early.
• Bladder decompensation: chronic outlet resistance causes detrusor hypertrophy → trabeculation, diverticula, then an atonic, high-residual bladder with overflow incontinence.
• Stasis complications: recurrent UTI and bladder calculi from incomplete emptying.

Complications of BPH treatment

• Alpha-1 blockers (e.g., tamsulosin): orthostatic hypotension/syncope (worse with nonselective agents) and intraoperative floppy iris syndrome — the exposure must be disclosed before cataract surgery.
• 5-alpha-reductase inhibitors (e.g., finasteride): gynecomastia, decreased libido, and a roughly 50% drop in serum PSA, which must be accounted for when interpreting screening values.
• TURP: TUR syndrome — dilutional hypotonic hyponatremia from absorbed hypo-osmolar irrigant, presenting with confusion, nausea, and visual changes (glycine-related); also retrograde ejaculation, bleeding, and urethral stricture.

Complications of prostate carcinoma

• Metastatic epidural spinal cord compression — emergency: vertebral metastasis with back pain, weakness, saddle anesthesia, or retention. Give corticosteroids and obtain urgent MRI of the entire spine, then radiation or surgery (NCCN).
• Pathologic fracture and osteoblastic bone lesions: elevated alkaline phosphatase with typically normal calcium.
• Chronic DIC: tumor tissue factor/urokinase release causing bleeding with low fibrinogen and elevated D-dimer.
• Ureteral obstruction from local trigonal invasion or nodal bulk.

Complications of cancer treatment

• GnRH agonist flare: transient testosterone surge can worsen cord compression — pretreat with an antiandrogen or use a GnRH antagonist.
• Androgen deprivation: osteoporosis, hot flashes, metabolic syndrome, and cardiovascular risk; NCCN advises bone density monitoring with calcium/vitamin D and antiresorptive therapy when indicated (osteonecrosis of the jaw is the antiresorptive risk).
• Radical prostatectomy: erectile dysfunction and stress incontinence. Radiation: proctitis, cystitis.

• Zonal anatomy is the whole trick: BPH arises in the transition zone (periurethral → obstruction early, DRE often unremarkable relative to symptoms); adenocarcinoma arises in the peripheral zone, posteriorly, which is why it is palpable as a hard nodule on DRE yet causes obstructive symptoms only late. A stem describing an asymptomatic man with a firm posterior nodule is cancer, not BPH.
• Perineural invasion is the classic histologic buzzword for prostatic adenocarcinoma; the other defining feature is loss of the basal cell layer — confirmed by absent p63/high-molecular-weight cytokeratin staining with positive AMACR (P504S) in malignant glands. Benign glands retain a two-cell layer.
• Gleason score = primary pattern + secondary pattern (not the worst plus the best, and not an average). Grade Group 1 = 3+3; Grade Group 2 (3+4) behaves better than Grade Group 3 (4+3) even though both sum to 7 — that ordering is the tested distinction.
• Osteoblastic bone metastases with elevated alkaline phosphatase and usually normal serum calcium are the classic pairing; new axial back pain in an older man is prostate cancer until proven otherwise. Back pain plus any neurologic deficit → corticosteroids and urgent whole-spine MRI, not a bone scan first.
• The single best next step after an abnormal DRE or persistently elevated PSA is not treatment but tissue: repeat/confirm PSA, then multiparametric MRI and ultrasound-guided biopsy for histologic diagnosis and grading (NCCN).
• PSA is organ-specific, not cancer-specific — prostatitis, instrumentation, retention, and BPH itself raise it. Conversely, finasteride roughly halves PSA, so an "apparently normal" PSA on a 5-alpha-reductase inhibitor may be falsely reassuring.
• Screening: USPSTF supports individualized shared decision-making for PSA screening in men aged 55–69 and recommends against routine screening at age 70 and older — the distractor is reflexive universal screening.
• Common distractor: BPH does not cause prostate cancer and is not premalignant; the precursor lesion is high-grade prostatic intraepithelial neoplasia.